PF-Atlas › Treatments › Inhaled GSK3008348

Inhaled GSK3008348

Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Mechanism class
Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s
Timeline
2-3 years
Risk profile
Low
Developer
GSK / UCSF
Key researchers
D. Sheppard

Overview

Inhaled delivery targets exact cells expressing αvβ6. Better lung specificity vs systemic PLN-74809.

How Inhaled GSK3008348 fits into IPF treatment

Inhaled GSK3008348 is classified as Level 2 (Phase II) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:

Inhaled GSK3008348 drug profileInhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2sClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Inhaled GSK3008348 for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.